Cytokine profile dynamics in ascites with advanced ovarian cancer

• Aleshikova Olga I.
• Antonova Irina B.
• Babaeva Nataliya A.
• Gerfanova Evgenia V.
• Ashrafyan Lev A.
• Kiselev Vsevolod I.
• Kuznetsov I.N.

AbstractIn the article survey results of cytokine Level dynamics in ascitic fluid of patients diagnosed with stage III—IV ovarian cancer during treatment (before neoadjuvant chemotherapy, after its completion and in case of ascites disease recurrence, in combination with Indole-3-Carbinol (I3C) and epigallocatechin-3-gallate (EGCG) containing drugs) are represented. It was possible to demonstrate that against the background of neoadjuvant chemotherapy (NCT) in tumor ascites there is clear trend to reduction of most proinflammatory cytokines concentration (to significantly lower levels in IL-6, IL-8, IL-10, Hu G-CSF, Hu-MCP, Hu MIP-1β, Hu TNF-α.) In ascitic recurrences of serous ovarian cancer (OC) concentrations of most levels of interleukins achieved after completion of therapy were more than 80% - IL-6 and less - IL-8, IL-2, IL-1β, etc., against the background of decreasing or not changing indicators - IL-7, IL-13, IL-17, G-CSF, GM-CSF, which allows to exclude some of them from diagnostic search for markers of disease progression and to re-evaluate their role in ovarian carcinogenesis.

Keywords:ovarian cancer, neoadjuvant chemotherapy, cytokines, ascites, chemoresistance, inflammation

References

1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods // Int. J. Cancer. 2018 Oct 23. doi: 10.1002/ijc.31937. PubMed PMID: 30350310

2. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. Geneva : World Health Organization, 2018. URL: http://apps.who.int/iris/bitstream/handle/10665/272596/9789241565585-eng.pdf .

3. World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP/248. United Nations, Department of Economic and Social Affairs, Population Division, 2017.

4. Zimmer С. Evolved for Cancer? Scientific American, 2008. URL: https://www.scientificamerican.com/article/evolved-for-cancer-2008-07/

5. Antonov V.G., Kozlov V.K. Pathogenesis of oncologic diseases: immune and biochemical phenomena and mechanisms. Tsitokiny i vo-spaleniye [Cytokines and inflammation]. 2004; 3 (1): 8-19. (in Russian)

6. Okin D., Medzhitov R. Evolution of inflammatory diseases. Curr. Biol. 2012; 22 (17): R733-R740.

7. l.M. Sharaphetdinovа, A.M. Mazitova, O.A. Kravtsova, L.I. Maltseva, E.Yu. Yupatov Association of polymorphism of genes of several proinflammatory cytokines and the risk of pre-eclampsia // Практ. мед. 2015. № 1 (86). С. 37-40. (in Russian)

8. Chistyakova G.N., Gazieva I.A., Remizova 1.1., et al. Evaluation of cytokine production during pregnancy complicated by the threat of termination in the first trimester. Fundamental'nye issledovaniya [Fundamental Research].2005; 5: 96-8. URL: http://www.fundamental-research.ru/ru/article/view?id=6109 . (in Russian)

9. Gombolevskaya N.A., Burmenskaya O.V., Demura T.A., Marchenko L.A., Kogan E.A., Trofimov D.Yu., Sukhikh G.T. Estimation of the mRNA expression of cytokine genes in the endometrium in chronic endometritis. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2013; 11: 35-40. (in Russian)

10. Miroshnichenko S.M., Kovalenko G.A., Russkikh G.S., Poterya-eva O.N., Panin L.E., Morphofunctional parameters of peritoneal macrophages of different mice strains at aseptic inflammation. Byulleten' Sibirskogo otdeleniya RAMN [Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences]. 2014; 1. URL: https://cyberleninka.ru/article/n/morfofunktsionalnye-pokazateli-peritonealnyh-makrofagov-razlichnyh-liniy-myshey-pri-asepticheskom-vospalenii . (дата обращения: 22.12.2018) (in Russian)

11. Sverdlov E.D. Unsolvable Problems of Biology: It Is Impossible to Create Two Identical Organisms, to Defeat Cancer, or to Map Organisms onto Their Genomes. Biokhimiya [Biochemistry]. 2018; 83 (4): 517-27. (in Russian)

12. Ashrafyan L.A. Possible pathogenetic types of sporadical ovarian cancer. Opukholi zhenskoy reproduktivnoy sistemy [Tumors of Female Reproductive System]/ 2012; (3-4): 112-9. (in Russian)

13. Halkia E., Chrelias G., Chrelias C., Esquivel J. 2017 Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal-Treatment Considerations. Gastroenterol. Res. Pract. 2018. Vol. 2018. Article ID 5284814. doi: 10.1155/2018/5284814. Published 2018 Apr 5.

14. Ashrafyan L.A., Kiselev V.I. Tumors of the reproductive organs (etiology and pathogenesis). Moscow: Dimitreyd Grafik Grupp, 2007. 216 р. (in Russian)

15. Aleshikova O.I., Antonova I.B., Babaeva N.A., Gerfanova E.V., Shender V.O., Ashrafyan L.A. Assessment of Cytokine Levels in Ascitic Fluid in Patients with

Ovarian Cancer Receiving Neoadjuvant Chemotherapy. Doktor.Ru. [Doctor.Ru]. 2018; 2 (146): 63-8. (in Russian)

16. Shender V.O., Pavlyukov M.S., Ziganshin R.H., Arapidi G.P., et al. Protrome-metabolome profiling of ovarian cancer ascities reveals novel components involved in intercellular communication. Mol Cell Proteomics. 2014; 13 (12): 3558-71.

17. Lane D., Matte I., Garde-Granger P. et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015; 15: 492. doi: 10.1186/s12885-015-1511-7.

18. Bodo E.L. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14 (6): e218-e228. URL: https://doi.org/10.1016/S1470-2045(12)70582-X .

19. Yue Wang, Rui Cheng Xu, Xiao Lei Zhang. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 22012; 59 (1): 145-55.

20. Maccio A., Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications - a review. J Mol Med. 2013; 91 (12): 1355-68.

21. Matte I., Lane D., Bachvarov D. et al. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer. 2014; 14: 288.

22. Alldredge J., Flies D., Higuchi T., et al. Impaired interleukin-10 signaling and ovarian cancer growth in the peritoneal cavity. J Clin Oncol. 2014; 32 (15. Suppl.): e22094-e22094.

23. Kolomeyevskaya N., Eng K.H., Khan A.N.H. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-a and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138 (2): 352-7.

24. Ashrafyan L.A., Kiselev V.I., Muizhnek E.L., Gerfanova E.V., Antonova I.B., Kuznetsov I.N., Aleshikova O.I. Current principles of effective therapy for ovarian cancer. Opukholi zhenskoy reproduktivnoy sistemy [Tumors of Female Reproductive System]. 2015 (2): 68-75. (in Russian)

25. Lupia M., Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer. 2017; 16 (1): 64. doi: 10.1186/s12943-017-0638-3. Published 2017 Mar 20.

26. Kiselev V.I., Kuznetsov I.N., Drukh V.M., Muyzhnek E.L. Drug regulation of gene activity. Voprosy biologicheskoy, meditsinskoy i farmat-sevticheskoy khimii [Problems of Biological, Medical and Pharmaceutical Chemistry]. 2016; 9: 28-39. (in Russian)

27. Li H., Zhang X., Fan W. 3,3'-Diindolylmethane suppresses ovarian cancer cell viability and metastasis and enhances chemotherapy sensitivity via STAT3 and Akt signaling in vitro and in vivo. Arch Biochem Biophys. 2018 Jul 21. doi: 10.1016/j.abb.2018.07.002.

28. Walters Haygood C.L., Arend R.C., Straughn J.M., Buchsbaum D.J. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells. 2014; 6 (4): 441-7.

29. Casey S.C., Amedei A., Aquilano K. et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015; 35, suppl. : S199-S223.

30. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 2017; 44: 67-71.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)